HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.

ABSTRACT: It is well documented that human epidermal growth factor receptor 2 (HER2) overexpression/amplification is associated with poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2-negative breast cancer patients. Here, we identified HER2 somatic mutations in tumors from 1348 unselected breast cancer patients by sequencing the entire HER2 coding region. All of these mutations were tested for in corresponding blood samples to determine whether they were somatic or germline mutations. We further investigated the associations between HER2 somatic mutations and recurrence-free survival and distant recurrence-free survival in this cohort of patients. We found that 27 of 1348 (2.0%) of these patients carried a HER2

SUBMITTER: Wang T 

PROVIDER: S-EPMC5406600 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature